• ALZN is trading 15% down at $0.99 today.
  • The movement follows Alzheon's announcement on July 6, 2026, detailing presentations of new clinical, imaging, and fluid biomarker results for its lead investigational therapy, valiltramiprosate/ALZ-801, at the 2026 Alzheimer's Association International Conference (AAIC).
  • The company highlighted new Phase 3 and long-term extension analyses reinforcing the drug's profile for APOE4/4 Alzheimer's patients.